Meeting
2023 ASCO Annual Meeting
Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.
Presenter
Yasmin Karimi, MD
University of Michigan Comprehensive Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT03625037
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7525)
DOI
10.1200/JCO.2023.41.16_suppl.7525
Abstract #
7525
Poster Bd #
76
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Speaker: Yasmin Karimi, MD
Videos & Slides
2024 ASCO Annual Meeting
EPCORE NHL‑1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.
Speaker: Julie Vose, MD, MBA
Videos & Slides
2024 ASCO Annual Meeting
Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.
Speaker: David Jacob Andorsky, MD
Videos & Slides
2021 ASCO Annual Meeting
Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.
Speaker: Michael Roost Clausen, MD, PhD